Immunoglobulin G immune response to SARS-CoV-2 vaccination in people living with multiple sclerosis within Multiple Sclerosis Partners Advancing Technology and Health Solutions

BACKGROUND: The impact of multiple sclerosis (MS) disease-modifying therapies (DMTs) on SARS-CoV-2 vaccination response is uncertain. METHODS: Post-SARS-CoV-2 vaccination blood samples across multiple DMTs were tested for SARS-CoV-2 immunoglobulin G (IgG) response. RESULTS: Three hundred twenty-two...

Descripción completa

Detalles Bibliográficos
Autores principales: Cohen, Jeffrey A, Bermel, Robert A, Grossman, Cynthia I, Hersh, Carrie M, Hyland, Megan, Mowry, Ellen M, Naismith, Robert, Naylor, Maria L, Nicholas, Jacqueline, Rajbhandar, Rajani, Singh, Carol M, Tintorè, Mar, Zabalza, Ana, Ziemssen, Tjalf, Williams, James R, Montalban, Xavier
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Short Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9131404/
https://www.ncbi.nlm.nih.gov/pubmed/34994577
http://dx.doi.org/10.1177/13524585211061343
Descripción
Sumario:BACKGROUND: The impact of multiple sclerosis (MS) disease-modifying therapies (DMTs) on SARS-CoV-2 vaccination response is uncertain. METHODS: Post-SARS-CoV-2 vaccination blood samples across multiple DMTs were tested for SARS-CoV-2 immunoglobulin G (IgG) response. RESULTS: Three hundred twenty-two people with MS were included; 91.9% received an mRNA vaccine. Post-vaccination reactive IgG rates (IgG index > 1) were 40% for anti-CD20 (32/80 patients); 41% for sphingosine 1-phosphate receptor modulators (S1PRM, 16/39); and 100% for all other classes, including the no DMT group. CONCLUSION: Anti-CD20 therapies and S1PRMs reduce IgG response to SARS-CoV-2 vaccination; IgG response is preserved with other DMTs.

Ejemplares similares